<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02107846</url>
  </required_header>
  <id_info>
    <org_study_id>PB-112-02a</org_study_id>
    <nct_id>NCT02107846</nct_id>
  </id_info>
  <brief_title>An Open-Label, Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112</brief_title>
  <official_title>A Phase 2a, Open-Label, Sequential Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112 (Plant Recombinant Human Glucocerebrosidase) in Enzyme Replacement Therapy-Naïve Subjects With Gaucher Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Protalix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Protalix</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, dose escalation study to evaluate the safety of oral PRX-112 and&#xD;
      pharmacokinetics of GCD in subjects with Gaucher disease naive to enzyme replacement therapy.&#xD;
      The dose levels of PRX-112 are 50 units, 100 units, 200 units and 400 units GCD. Subjects&#xD;
      will receive once daily oral administrations of PRX-112 for 5 consecutive days at each dose&#xD;
      level with a 2-day washout period between doses.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve</measure>
    <time_frame>24 hours</time_frame>
    <description>Blood samples for GCD level every 2 hours for 24 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>7 Days</time_frame>
    <description>Reporting of adverse events collected daily</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Gaucher Disease</condition>
  <arm_group>
    <arm_group_label>50 Units</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRX-112 50 Units daily for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 Units</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRX-112 100 Units daily for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 Units</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRX-112 200 Units daily for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>400 Units</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRX-112 400 Units daily for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRX-112</intervention_name>
    <arm_group_label>100 Units</arm_group_label>
    <arm_group_label>200 Units</arm_group_label>
    <arm_group_label>400 Units</arm_group_label>
    <arm_group_label>50 Units</arm_group_label>
    <other_name>Carrot Cells Expressing Recombinant Human Glucocerebrosidase</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female age 18 or older&#xD;
&#xD;
          -  Historical diagnosis of Gaucher disease by low leukocyte GCD activity level&#xD;
&#xD;
          -  Haemoglobin ≥ 10 g/dL&#xD;
&#xD;
          -  Body mass index (BMI) of 18 kg/m2-30 kg/m2 inclusive&#xD;
&#xD;
          -  Subject is able to provide written informed consent&#xD;
&#xD;
          -  Female subjects of child bearing potential must not be pregnant or lactating with a&#xD;
             negative urine pregnancy test result at the screening visit.&#xD;
&#xD;
          -  Female subjects of child-bearing potential and male subjects with female partners of&#xD;
             childbearing potential must use two methods of contraception at all times during the&#xD;
             study, one of which must be a barrier method. Acceptable methods of contraception are&#xD;
             oral contraceptives, barrier methods (male condom, female condom, diaphragm, cervical&#xD;
             cap, spermicide or intrauterine device), surgical sterility (documented doctor's&#xD;
             report of vasectomy, hysterectomy and/or bilateral oophorectomy) and/or postmenopausal&#xD;
             status (defined as at least 1 year without menses as demonstrated by medical history&#xD;
             or subject report).&#xD;
&#xD;
          -  Negative laboratory tests for HIV, HBsAg and HCV at the screening visit&#xD;
&#xD;
          -  Naïve to any previous ERT or have received the last ERT treatment 12 months before&#xD;
             signing IC&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of a gastrointestinal (GI) disease affecting motility or absorption&#xD;
&#xD;
          -  Subjects with any history of allergic response to biological drugs or other allergies&#xD;
             deemed clinically significant by the Investigator&#xD;
&#xD;
          -  Reported history of alcohol or drug abuse&#xD;
&#xD;
          -  Subject has donated blood in the 3 months prior to screening or subject has received&#xD;
             plasma derivatives in the 6 months prior to screening&#xD;
&#xD;
          -  Use of any investigational drug or participation in another clinical trial in the 3&#xD;
             months prior to screening (subject report)&#xD;
&#xD;
          -  Subjects who have previously received ERT with positive anti-human plant recombinant&#xD;
             GCD (prGCD) antibodies&#xD;
&#xD;
          -  Clinical evidence of any active significant disease that could potentially compromise&#xD;
             the ability of the Investigator to evaluate or interpret the effects of the study&#xD;
             treatment on safety assessment, thus increasing the risk to the subject to&#xD;
             unacceptable levels&#xD;
&#xD;
          -  Presence of any medical, emotional, behavioural or psychological condition that, in&#xD;
             the judgement of the Investigator, would interfere the compliance requirements of the&#xD;
             study&#xD;
&#xD;
          -  Subject has used any medication (excluding acetaminophen or dyprione) within 7 days of&#xD;
             screening, including laxatives, teas and food additives known to be used for the&#xD;
             treatment of constipation or diarrhea&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>April 4, 2014</study_first_submitted>
  <study_first_submitted_qc>April 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2014</study_first_posted>
  <last_update_submitted>September 27, 2016</last_update_submitted>
  <last_update_submitted_qc>September 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gaucher Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

